Are overweight or have obesity, especially if they also have diabetes or other health risks (Trulicity and Mounjaro are not indicated for the treatment of overweight or obesity, however)
However, combined, they control over 90% of the GLP-1 market, both globally and in the U.S
A degraded peptide from improper storage might produce inconsistent appetite suppression and, potentially, inconsistent digestive side effects from dose to dose
As we look ahead, it is evident that GLP-1 RAs are revolutionizing diabetes care
GLP-1s should be considered an extra tool to help you follow through on healthier food choices, but they dont do the work for you
The short answer: if you want results on paper, retatrutide leads